ASX Announcements Due to legal restrictions, only residents of Australia and New Zealand may access ASX announcements that contain information or materials relating to any capital raising. Keyword Search Year None20202019 Date Title 22 October 2020 Remestemcel Controlled Study in Crohns & Ulcerative Colitis 13 October 2020 Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment 02 October 2020 Update on BLA for Graft Versus Host Disease 01 October 2020 Trading Halt 15 September 2020 MSB Wins Fierce Biotech Innovation Award for Remestemcel-L 10 September 2020 Appendix 2A 07 September 2020 Change in substantial holding 04 September 2020 DSMB Recommends Continuation of Phase 3 COVID-19 Trial 02 September 2020 Ethics Approval to Treat COVID-19 Patients in Australia 02 September 2020 Change in substantial holding 27 August 2020 MSB Annual Financial Results and Operational Progress 27 August 2020 Annual Financial Results Presentation 27 August 2020 Preliminary Final Report including Appendix 4E 26 August 2020 Mesoblast 2020 Full Year Financial Results Webcast 24 August 2020 Change in substantial holding 21 August 2020 Change in substantial holding 20 August 2020 Appendix 2A and Appendix 3G 14 August 2020 ODAC Votes in Favor of Remestemcel-L for GvHD 13 August 2020 Trading Halt 12 August 2020 Change in substantial holding - Amendment 12 August 2020 Change in substantial holding - Amendment 11 August 2020 Update on Scheduled FDA Advisory Committee Meeting 10 August 2020 Change in substantial holding 07 August 2020 Change in substantial holding 06 August 2020 Appendix 2A 06 August 2020 Proposed issue of Securities - MSB 30 July 2020 COVID-19/GVHD Update, Quarterly Report and Appendix 4C 24 July 2020 Mesoblast Expands Executive Leadership Team 21 July 2020 FDA Advisory Committee Sets Review Date for Remestemcel-L 07 July 2020 Appendix 3B, 2A with prospectus- Kentgrove Capital 06 July 2020 EAP for Remestemcel-L in Children with MIS-C due to COVID-19 30 June 2020 Appendix 2A 24 June 2020 Appendix 3G with 3Ys 16 June 2020 Appendix 2A 12 June 2020 S&P DJI Announces June 2020 Quarterly Rebalance 01 June 2020 Appendix 2A 01 June 2020 Remestemcel-L Improves Outcomes in Inflammatory Lung Disease 28 May 2020 MSB Reports Q3 Financial Results and Operational Highlights 28 May 2020 Third Quarter Results Presentation 28 May 2020 Third Quarter Financial Results on Form 6-K 27 May 2020 Change in substantial holding 25 May 2020 3 Articles on RYONCIL GvHD Trial Results Published in BBMT 19 May 2020 Change in substantial holding 18 May 2020 Cleansing Notice 15 May 2020 Appendix 2As 13 May 2020 Proposed issue of Securities - MSB 13 May 2020 MSB Completes Financing For Covid-19 ARDS Manufacturing 11 May 2020 Trading Halt 06 May 2020 First Patients Dosed in Phase 2/3 Trial for COVID-19 ARDS 30 April 2020 Phase 2/3 Trial in COVID-19 ARDS Begins Enrollment 29 April 2020 Appendix 4C - quarterly 24 April 2020 83% Survival in COVID-19 ARDS Patients with Remestemcel-L 17 April 2020 Inflammatory Lung Disease Outcomes For Presentation at ISCT 09 April 2020 US NIH Trials Network to Conduct COVID-19 Phase 2/3 Trial 06 April 2020 FDA Clears IND for Remestemcel Use in COVID-19 ARDS Patients 01 April 2020 FDA Accepts BLA for RYONCIL and Agrees to Priority Review 30 March 2020 Ischemic End Stage HF Outcomes at Virtual ACC Annual Meeting 20 March 2020 Change of Director's Interest Notice 17 March 2020 Appendix 2A 10 March 2020 Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease 27 February 2020 Mesoblast Provides Half Year Results and Corporate Update 27 February 2020 Half Year Financial Results Presentation 27 February 2020 Half Year Report and Accounts (including Appendix 4D) 25 February 2020 Mesoblast Half Year FY 2020 Financial Results Analyst Call 24 February 2020 Ryoncil Results in Children with Acute GvHD Presented at TCT 21 February 2020 Appendix 3G 20 February 2020 Positive Outcomes Using Remestemcel-L in Chronic GVHD 07 February 2020 Appendix 2A 03 February 2020 Mesoblast Submits Completed BLA for Ryoncil to US FDA 29 January 2020 Appendix 4C - quarterly 24 January 2020 Appendix 2A 15 January 2020 Biotech Showcase Presentation 15 January 2020 MSB Presents Commercial Plans at 2020 Biotech Showcase 02 January 2020 Appendix 2A 02 January 2020 MSB Files GvHD Clinical Efficacy and Safety Data with US FDA
